NightstaRx Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NightstaRx Limited - overview
Established
2013
Location
London, England, UK
Primary Industry
Pharmaceuticals
About
Founded in 2013 and based in London, UK, NightstaRx Limited operates as a developer of gene therapies for inherited retinal diseases such as choroideremia, X-linked retinitis pigmentosa, and best vitelliform macular dystrophy.
Current Investors
New Enterprise Associates, Wellington Management, Redmile Group
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Epidemiology, Optometrists & Opticians Products and Services, Pharmaceutical Research & Development
Company Stage
Mature
Total Amount Raised
Subscriber access only
NightstaRx Limited - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | (23,778,000) | (29,000) | - | - | - | - |
| Operating Income (USD) | (23,778,000) | (29,000) | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | (22,138,000) | (16,528,000) | - | - | - | - |
| % Net Margin | - | - | - | - | - | - |
NightstaRx Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.